ArticleCureus2026
Association of the Model for End-Stage Liver Disease (MELD) Score With Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpontaneous bacterial peritonitis (SBP) is a common and serious complication of decompensated liver cirrhosis, associated with increased morbidity, mortality, and prolonged hospitalization. Early identification of patients at high risk of SBP is essential to facilitate prompt diagnosis and timely treatment. The Model for End-Stage Liver Disease (MELD) score is a validated prognostic tool that reflects the severity of liver dysfunction and predicts mortality in patients with cirrhosis. However, its role in identifying patients at increased risk of SBP remains uncertain, particularly in resource-limited settings. This study aimed to determine the association between the MELD score and SBP in patients with liver cirrhosis. MATERIALS AND
methodsA case-control study was conducted in the Department of Medicine at Khyber Teaching Hospital, Peshawar, from March 15 to September 14, 2024. A total of 104 patients with liver cirrhosis and ascites (52 cases with SBP and 52 controls without SBP) were enrolled. SBP was defined as an ascitic fluid neutrophil count >250 cells/mm³. A MELD score >15 was defined as high. Data were analyzed using SPSS Statistics version 25 (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.).
resultsThe mean age of the cases was 58.23 ± 8.51 years, and that of the controls was 53.27 ± 10.81 years. Hepatitis C virus was the leading etiology, accounting for 48.1% of cases. A high MELD score was observed in 36 (69.2%) cases and 18 (34.6%) controls. The association between a high MELD score and SBP was statistically significant (ꭓ² = 12.48, p < 0.001), with an odds ratio of 4.25 (95% CI: 1.90-9.53).
conclusionsA high MELD score is significantly associated with the development of SBP in patients with liver cirrhosis. It serves as a reliable bedside clinical marker for identifying patients at higher risk of this severe complication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.